PMPrasanna H. Megalamani

Prasanna H. Megalamani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Prasanna H. Megalamani has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular dynamics based comparative analysis of native Urtica dioica agglutinin and its engineered mutant UDAM5

    by Maruti J. Gurav, Prasanna H. Megalamani, Nagarjuna Prakash Dalbanjan, S.K. Praveen Kumar, Vishwanath B. Chachadi


  • Plastics: an overview of applications, potential health risk, carcinogen to restriction

    by Maruti J. Gurav, Prasanna H. Megalamani, Nagarjuna Prakash Dalbanjan, Manasa J, Ashwini S. Sanji, Veeresh S, Ajay Kumar Oli, S.K. Praveen Kumar, Vishwanath B. Chachadi


  • Adhesion to aggression: unravelling sLea and sLex in cancer metastasis

    by Prasanna H. Megalamani, Anne Harduin-Lepers, J. Manasa, Maruti J. Gurav, Ashwini S. Sanji, Vishwanath B. Chachadi

    The sialylated Lewis antigens sLea and sLex are terminal glycans that are crucial for adhesive and signalling functions during cancer metastasis. As high affinity ligands for E-, P-, and L-selectins, these epitopes allow tumor cells to arrest, evade immune cells and extravasate in the vascular microenvironment, mimicking leukocyte trafficking. This review provides a detailed analysis of sLea/x biosynthesis, structure, function and their role in metastatic progression. We focus on the differential roles of glycoprotein versus glycolipid associated sLea/x, their glycosyltransferase mediated synthesis and the spatial trafficking mechanisms that govern their surface expression. We also highlight the carrier scaffolds and glyco-enzyme hierarchies that present the ligand across different cancers, mucins, integrins and glycosphingolipids. A section is dedicated to how exosome bound sLea/x primes pre-metastatic niche and immune modulation, a new perspective on glycan mediated systemic signaling. We also compile validated tumor specific profiles of sLea/x across several cancer types, linking structural expression to metastatic phenotypes. Additionally, we discuss emerging strategies targeting sLea/x pathways from glycosylation inhibitors to selectin blocking therapeutics and the translational challenges and opportunities. Overall, this synthesis shows the importance of sLea and sLex in metastasis and lays the foundation for their use as biomarkers and therapeutic targets in precision oncology. Graphical abstract


  • Lectin-glycan interactions: a comprehensive cataloguing of cancer-associated glycans for biorecognition and bio-alteration: a review

    by Maruti J. Gurav, J. Manasa, Ashwini S. Sanji, Prasanna H. Megalamani, Vishwanath B. Chachadi

    This comprehensive review meticulously compiles data on an array of lectins and their interactions with different cancer types through specific glycans. Crucially, it establishes the link between aberrant glycosylation and cancer types. This repository of lectin-defined glycan signatures, assumes paramount importance in the realm of cancer and its dynamic nature. Cancer, known for its remarkable heterogeneity and individualized behaviour, can be better understood through these glycan signatures. The current review discusses the important lectins and their carbohydrate specificities, especially recognizing glycans of cancer origin. The review also addresses the key aspects of differentially expressed glycans on normal and cancerous cell surfaces. Specific cancer types highlighted in this review include breast cancer, colon cancer, glioblastoma, cervical cancer, lung cancer, liver cancer, and leukaemia. The glycan profiles unveiled through this review hold the key to tailor-made treatment and precise diagnostics. It opens up avenues to explore the potential of targeting glycosyltransferases and glycosidases linked with cancer advancement and metastasis. Armed with knowledge about specific glycan expressions, researchers can design targeted therapies to modulate glycan profiles, potentially hampering the advance of this relentless disease. Graphical Abstract